Speaker:
Title:
Investigating Effects of AXL Inhibition on the Tumor Immune Microenvironment
Abstract:
AXL, a receptor tyrosine kinase implicated in cancer progression, is known to facilitate drug resistance via bypass signaling. AXL is a promising therapeutic target, with many studies focusing on how its inhibition affects cancer cells, but few groups have explored the effects of AXL inhibition on immune cells in the tumor microenvironment (TME). Here, we present our work toward building an in vitro model of cancer-immune cell interactions to gain a quantitative, mechanistic understanding of AXL’s role in the TME and anti-tumor immunity.